From Research to Academic Startup
VIS has launched a new program for researcher entrepreneurship for researchers with an innovative idea or technology that has the potential to become the next generation product or service. Are you motivated to explore commercial opportunities and realize your research in practice? Then this program is for you.
Main content
VIS TILT – Academic entrepreneurship presents the Researcher Entrepreneurship Program in Eitri on Friday 4 October from 10 to 13.
The event is primarily aimed at researchers, especially PhD students, postdoctoral fellows, and researchers at the Faculty of Medicine who are interested in how they can take their research from academia to the commercial market. Other interested parties are also welcome to attend the seminar.
This event provides a unique opportunity for researchers at the Faculty of Medicine to explore how their academic work can be transferred from the laboratory to commercial solutions. Participants will gain insights into entrepreneurship, access valuable networks, and engage in interactive case work designed to develop an entrepreneurial mindset.
Language: English.
Agenda
Kl 10.00 -10.15 Coffee and mingling
Kl 10.15 -11.00 Introducing VIS & TILT: VIS’ brand-new entrepreneurship program for researchers. Tailored to provide researchers with entrepreneurial skills, expert advisory services and access to capital and networks. Recruitment of pilot participants in progress!
Kl 11.00 -12.00 Lunch and case work: Train your entrepreneurial mindset with real-life cases (and some just for fun). Or maybe you would like to share your own idea? Here is your chance!
Kl 12.00 -12.50 Inspirational talks: Showcasing the journey from academia to start-up.
- Pluvia Biotech - with Ann Kari Grindheim, Director of non-clinical development.
“Development of pharmacological chaperones for the treatment of PKU”.
Pluvia is a preclinical stage biotech spin-out from Department of Biomedicine, University of Bergen, targeting inherited diseases caused by protein misfolding. Their first target is Phenylketonuria (PKU) - an orphan indication with clear unmet needs.
- NordicNeuroLab - with Thomas Lie Omdahl, CEO.
“From brain research to commercialization - Health technology from Bergen".
NordicNeuroLab provides products and solutions that define the field of functional MR imaging.
- Miphic - with Gennady Nikitin, Founder and CEO.
“High-throughput mitochondrial precision medicine platform”.
Miphic performs multiparametric screening within three domains; metabolic drug discovery, personalized medicine choice, and fundamental research on metabolism.
- Noteless - with Sarankan Sivakanesan, Co-Founder and COO.
“Noteless believes in a healthcare service where care comes first. Our vision is to give healthcare personnel the freedom to focus fully on the patient, with AI technology doing the rest.”
